Mysterious drug pricing group reveals who is running it — but not donors

Published



A new advocacy group advocating policies favorable to the pharmaceutical industry last week immediately faced, and pushed back against, accusations that it is a front for the pharmaceutical lobby, and declined to disclose who gave it funding.

The small lobbying firm CGCN Group said on Friday that it created the new group, the Alliance to Protect Medical Innovation. Drug pricing reform activists and several reports questioned who was behind the group earlier in the week, after the alliance sprung into life the previous week with no mention of who is on the staff or who funds it.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.